Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis
Primary Purpose
Hypersensitivity
Status
Completed
Phase
Phase 4
Locations
United Kingdom
Study Type
Interventional
Intervention
Artificial Tear Supplement
Cold compress
Anti-allergic Medication
Sponsored by
About this trial
This is an interventional treatment trial for Hypersensitivity focused on measuring Ocular allergy, Tear supplement, Cold compress
Eligibility Criteria
Inclusion Criteria:
- history of seasonal allergic conjunctivitis or seasonal allergic rhinoconjunctivitis (seasonal hay fever) that is not currently active.
Exclusion Criteria:
- eye surgery in the last 3 months
- active eye condition
- adverse reaction to ocular drugs or dyes
- history of anaphylaxis (severe systemic allergic reaction)
- use any ocular medication or systemic medications (antihistamines, mast cell stabilisers, non-steroidal anti-inflammatory drugs or steroids) at least 14 days prior to the start and for the duration of the study
Sites / Locations
- National Pollen and Aerobiology Unit
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
No Intervention
Active Comparator
Active Comparator
Active Comparator
Arm Label
No Treatment
Artificial Tear Supplement
Cold compress
Anti-allergic Medication
Arm Description
Exposure to grass pollen only
Preservative free Hypromellose Eye Drops BP 0.3% w/v preservative free - MHRA product licence number:23097/0006
Cooled gel eye mask http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue
ELESTAT® (epinastine HCl ophthalmic solution) 0.05% Initial U.S. Approval: 2003 H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis
Outcomes
Primary Outcome Measures
Symptoms
Short questionnaire Ocular allergy symptomology was also measured using the eye symptom section from the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) on a 0 to 6 scale, with the summed score for itching, watering, swelling and soreness resulting in a summed score between 0 and 24. A higher score indicates a worse outcome (more severe symptoms)
Ocular Redness
Bulbar and limbal redness will be observed with a slit lamp biomicroscope and graded using a validated scale
• The 'Efron' grading scale consists of 5 pictures of eyes of increasing severity of blood vessels over the white of the eye, with the clinician selecting the image closest to what they observe on the patient (0 indicating a white eye and 4 a very irritated eye). There are no subscales
Ocular Temperature
Ocular surface temperature will be measured with an infra-red camera
Secondary Outcome Measures
Full Information
NCT ID
NCT01569191
First Posted
March 27, 2012
Last Updated
July 24, 2017
Sponsor
Aston University
Collaborators
University of Worcester
1. Study Identification
Unique Protocol Identification Number
NCT01569191
Brief Title
Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis
Official Title
Investigating the Efficacy of Artificial Tear Supplements and Cold Compresses for the Treatment of Seasonal Allergic Conjunctivitis
Study Type
Interventional
2. Study Status
Record Verification Date
July 2015
Overall Recruitment Status
Completed
Study Start Date
March 2012 (undefined)
Primary Completion Date
November 2012 (Actual)
Study Completion Date
February 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Aston University
Collaborators
University of Worcester
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Seasonal allergic conjunctivitis (SAC) is an irritating eye condition that affects many people, caused by hypersensitivity to normally harmless substances such as pollen, and often accompanies seasonal hay fever. Treatments that can be used before initiating medical therapy include artificial tear supplements (ATS) and cold compresses (CC). However, there is no evidence in the scientific literature that demonstrates their efficacy compared to no treatment or their combined effect with anti-allergic medication. Therefore the investigators aim to examine the efficacy of ATS and CC alone, in comparison to anti-allergic medication, and CC in combination with anti-allergic medication. In addition, the investigators also aim to determine the time course of ocular allergic reactions. At the end of the study the investigators will be able to see whether or not ATS and CC are effective in treating SAC.
Detailed Description
There will be a total of 6 study visits, each lasting approximately 1 hour and separated by at least 2 days. At the beginning of each visit, a set of measurements will be taken by an experienced optometrist. These are:
What symptoms you are feeling and how severe they are - you will be asked to complete a short questionnaire about how your eyes currently feel.
The redness and temperature of your eyes - the front surface of both eyes will be photographed using digital cameras.
After these measurements we will ask you to stand inside a specially designed room where the environment can be controlled by a computer. The pollen that you were found to be allergic to will then be introduced into the atmosphere of the room, so that the signs and symptoms of SAC can be induced - this is intentional, but normally resolves within a few hours with no treatment. At each visit, you will experience a different duration (no longer than 10 minutes) and either no treatment, artificial tear supplement (ATS; preservative free ocular lubricant), cold compress (CC; cooled gel eye mask) or anti-allergic medication (epinastine hydrochloride 500μg/mL). The measurements will then be repeated even 5 minutes for an hour.
After the final set of measurements, the front surface of your eyes will be assessed using a temporary dye to highlight using a blue light any changes. Fluorescein dye does not sting, lasts only a few minutes and has no effect on vision or driving. However it may cause a self limiting mild allergic reaction where the eyes become red, irritated and sore but this is highly unlikely as there are no known reported cases. In the unlikely event this does happen the experienced optometrist is immediately available to manage the condition.
The anti-allergic drug epinastine hydrochloride (Elestat, Allergan) is a prescription only medicine indicated for the treatment of allergic conjunctivitis. As with all medications, there are potential side effects - although uncommon (1 in 10 to 1 in 100 people), there may be a slight burning sensation on application but this temporary and subsides quickly. The epinastine formulation also contains preservatives called benzalkonium chloride and disodium edetate. As with fluorescein sodium, these may cause a self limiting mild allergic reaction. In the unlikely event this does happen the experienced optometrist is immediately available to manage the condition.
Study Length and Reimbursement Each of the 6 measurement visits is separated by 7 days therefore the total study length for each participant is 6 weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypersensitivity
Keywords
Ocular allergy, Tear supplement, Cold compress
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
18 (Actual)
8. Arms, Groups, and Interventions
Arm Title
No Treatment
Arm Type
No Intervention
Arm Description
Exposure to grass pollen only
Arm Title
Artificial Tear Supplement
Arm Type
Active Comparator
Arm Description
Preservative free Hypromellose Eye Drops BP 0.3% w/v preservative free - MHRA product licence number:23097/0006
Arm Title
Cold compress
Arm Type
Active Comparator
Arm Description
Cooled gel eye mask http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue
Arm Title
Anti-allergic Medication
Arm Type
Active Comparator
Arm Description
ELESTAT® (epinastine HCl ophthalmic solution) 0.05% Initial U.S. Approval: 2003 H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis
Intervention Type
Other
Intervention Name(s)
Artificial Tear Supplement
Other Intervention Name(s)
Hypromellose is also sold as Isopto plain eye drops
Intervention Description
artificial tear supplement (Hypromellose)
Intervention Type
Device
Intervention Name(s)
Cold compress
Other Intervention Name(s)
Eye-gel-mask-blue
Intervention Description
Cold compress bag fill with temperature retention gel placed over closed eyes Sold by http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue
Intervention Type
Drug
Intervention Name(s)
Anti-allergic Medication
Other Intervention Name(s)
ELESTAT® (epinastine HCl ophthalmic solution) 0.05%
Intervention Description
1 drop on single occasion after exposure to grass pollen
Primary Outcome Measure Information:
Title
Symptoms
Description
Short questionnaire Ocular allergy symptomology was also measured using the eye symptom section from the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) on a 0 to 6 scale, with the summed score for itching, watering, swelling and soreness resulting in a summed score between 0 and 24. A higher score indicates a worse outcome (more severe symptoms)
Time Frame
1 hour
Title
Ocular Redness
Description
Bulbar and limbal redness will be observed with a slit lamp biomicroscope and graded using a validated scale
• The 'Efron' grading scale consists of 5 pictures of eyes of increasing severity of blood vessels over the white of the eye, with the clinician selecting the image closest to what they observe on the patient (0 indicating a white eye and 4 a very irritated eye). There are no subscales
Time Frame
1 hour
Title
Ocular Temperature
Description
Ocular surface temperature will be measured with an infra-red camera
Time Frame
1 hour
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
history of seasonal allergic conjunctivitis or seasonal allergic rhinoconjunctivitis (seasonal hay fever) that is not currently active.
Exclusion Criteria:
eye surgery in the last 3 months
active eye condition
adverse reaction to ocular drugs or dyes
history of anaphylaxis (severe systemic allergic reaction)
use any ocular medication or systemic medications (antihistamines, mast cell stabilisers, non-steroidal anti-inflammatory drugs or steroids) at least 14 days prior to the start and for the duration of the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James Wolffsohn, PhD
Organizational Affiliation
Aston University
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Pollen and Aerobiology Unit
City
Worcester
ZIP/Postal Code
WR2 6AJ
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis
We'll reach out to this number within 24 hrs